CAMBRIDGE, MA / ACCESSWIRE / April 22, 2024 /Moderna, Inc. (NASDAQ: MRNA) announced a contract with Brazil’s Ministry of Health (Ministério da Saúde) to source its mRNA COVID-19 vaccine as a component of Brazil’s 2024 national COVID-19 vaccine. Vaccination campaign programme. This contract follows the approval by the Brazilian Health Regulation Agency (ANVISA) of Moderna’s COVID-19 vaccine in March 2024, which encodes the spike protein of the XBB. 1. 5 sublineage of SARS-CoV-2 for active immunization for the prevention of COVID-19. in children six months and older.
“We are proud to collaborate with the Ministry of Health to supply our mRNA COVID-19 vaccine for the first time in Brazil as part of the national vaccination campaign,” said Stéphane Bancel, CEO of Moderna. “This agreement underscores our commitment to global fitness and our role in supporting Brazil’s efforts to protect its citizens from COVID-19. We look forward to collaborating with the Ministry of Health to support fitness safety in Brazil. “
Under the contract, 12. 5 million doses of Moderna’s mRNA COVID-19 vaccine are expected to be delivered in the second quarter of 2024, marking a vital milestone in Brazil’s ongoing efforts to combat COVID-19. The partnership between Moderna and the Ministry of Health reflects a shared commitment to public health and the importance of national vaccination crusades. This contract is expected to contribute to Brazil’s national vaccination crusade and contribute to the global effort to combat the lingering risk of COVID-19.
The World Health Organization (WHO) has decided that the ancestral strain and related variants are no longer circulating in humans. To ensure that the updated vaccines provide the maximum physically powerful immune reaction against the dominant circulating variants, regulators and global public health agencies have recommended that COVID-19 vaccines be upgraded to an XBB. 1. 5 monovalent composition. Moderna has generated preclinical and clinical data on its monovalent XBB. 1. 5 vaccine candidate that exhibits an immune reaction opposite to the XBB sublineages and SARS-CoV-2 virus strains that have been circulating lately, adding JN. 1.
About Moderna
Moderna is a leader in creating mRNA-based medicines. Through advancements in mRNA technology, Moderna is reinventing the way drugs are made and transforming the way we treat and prevent disease for everyone. Working at the intersection of science, technology, and fitness for more than a decade, the company has developed drugs with unprecedented speed and efficiency, adding one of the earliest and most effective COVID-19 vaccines.
Moderna’s mRNA platform has enabled the advancement of therapies and vaccines against infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. With an exclusive culture and a global team driven through Moderna’s values and mindset to responsibly replace the long-term of human health. , Moderna strives to achieve the greatest imaginable effect on other people through mRNA drugs. To learn more about Moderna, visit modernatx. com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube, and LinkedIn. .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and adds statements regarding: the Company’s contract with the Brazilian Ministry of Health for the source of the Moderna’s COVID -19 vaccine as a component of Brazil’s national program. vaccination crusade; planned delivery of Moderna COVID-19 vaccines; and the ability of Moderna’s COVID-19 vaccine to provoke an immune reaction opposite to existing circulating strains of SARS-CoV-2. In some cases, forward-looking statements may be referred to by terms such as “will,” “may,” “deserve,” “may,” “expect,” “intend,” “plan,” “target,” “anticipate. ” , “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of those terms or other comparable terminology, not all forward-looking statements involve those terms. The forward-looking statements included in this release. press are not promises or guarantees, and you should not place undue reliance on such forward-looking statements because they involve known and unknown dangers, uncertainties and other matters, many of which are beyond Moderna’s control, and may cause actual effects to differ materially from those expressed. These hazards, uncertainties and other items include, but are not limited to, the hazards and uncertainties described below in Moderna’s Annual Report on Form 10-K. for the year ended December 31, 2023, filed with the United States Securities and Exchange Commission. Exchange Commission (SEC), as well as Moderna’s upcoming filings with the SEC, which will be found on the SEC’s online website at www. sec. gov. Except as required by law, Moderna disclaims any objective or duty to update or revise any forward-looking statements involved in this presentation whether as a result of new information, long-term developments or otherwise. These forward-looking statements are based on Moderna’s existing expectations and speak only as of the date of this press release.
Moderna Contacts:
Media: Luke Mircea Willats Senior Director, Luke. Mirceawillats@modernatx. com Communications
Investors: Lavina TalukdarSenior Vice President & Head of inversores617-209-5834Lavina. Talukdar@modernatx. com Relationships
SOURCE: Moderna, Inc.